At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness Trial of Tobacco Cessation Treatments Among Cancer Patients Who Smoke
In Brief
A Phase 4 clinical trial evaluating Transdermal Nicotine Patch, Standard Telephone Counseling, and 3 other interventions for Smoking Cessation and Cancer. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline treatment and 7 smoking cessation coaching calls with a cancer focus will be compared against an active comparator modeled after standard quitline treatments (2 weeks of nicotine patch therapy with 3 phone coaching calls). Approximately 50 participants will be recruited to generate estimates of the effects, acceptability, costs, and equity of enhanced treatment (vs. standard treatment), with the primary outcome being abstinence from smoking 26 weeks after trying to quit.
Study Details
Timeline
Interventions
a stop smoking aid, 21 milligrams(mg), 14mg, or 7mg of nicotine delivered over 24 hours
3 brief telephone-based smoking cessation counseling sessions
12 weeks of an oral smoking cessation medication
7 telephone-based smoking cessation counseling sessions adapted for cancer patients
Publicly funded treatment resources including the SmokefreeTXT program sponsored by the National Cancer Institute and the Wisconsin Tobacco Quit Line.